Biopharmaceutical classification based on solubility and dissolution: A reappraisal of criteria for hypothesis models in the light of the experimental observations

Basic and Clinical Pharmacology and Toxicology

Volumn 106, Issue 3, 2010, Pages 168-172

  Charkoftaki, Georgia ^a   Dokoumetzidis, Aristides ^a   Valsami, Georgia ^a   MacHeras, Panos ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AQUEOUS SOLUTION; CONFERENCE PAPER; DRUG CLASSIFICATION; DRUG DIFFUSION; DRUG SOLUBILITY; GASTROINTESTINAL MOTILITY; HYDRODYNAMICS; HYPOTHESIS; IN VITRO STUDY; PRIORITY JOURNAL; THEORETICAL MODEL;

ANIMALS; BIOPHARMACEUTICS; GASTROINTESTINAL MOTILITY; HUMANS; INTESTINAL ABSORPTION; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; SOLUBILITY;

EID: 77149153685     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2009.00506.x     Document Type: Conference Paper

References (50)

1. Macheras PE, Symillides MY. Toward a quantitative approach for the prediction of the fraction of dose absorbed using the absorption potential concept. Biopharm Drug Dispos 1989 10 : 43 53.
2. Sinko PJ, Leesman GD, Amidon GL. Predicting fraction dose absorbed in humans using a macroscopic mass balance approach. Pharm Res 1991 8 : 979 988.
3. Oh D-M, Curl RL, Amidon GL. Estimating the fraction absorbed from suspensions of poorly soluble compounds in humans: a mathematical model. Pharm Res 1993 10 : 264 270.
4. Kalampokis A, Argyrakis P, Macheras P. Heterogeneous tube model for the study of small intestinal transit flow. Pharm Res 1999 16 : 87 91. (Pubitemid 29047462)
5. Kalampokis A, Argyrakis P, Macheras P. A heterogeneous tube model of intestinal drug absorption based on probabilistic concepts. Pharm Res 1999 16 : 1764 1769.
6. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995 12 : 413 420.
7. FDA/CDER. Guidance for Industry, Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. Washington, DC, August 2000.
8. Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 2005 22 : 11 23.
9. Benet L, Amidon G, Barends D, Lennernas H, Polli J, Shah V et al. The use of BDDCS in classifying the permeability of marketed drugs. Pharm Res 2008 25 : 483 488.
10. Yazdanian M, Briggs K, Jankovsky C, Hawi A. The "high solubility" definition of the current FDA Guidance on Biopharmaceutical Classification System may be too strict for acidic drugs. Pharm Res 2004 21 : 293 299.
11. Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP et al. Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res 2002 19 : 921 925.
12. Rinaki E, Dokoumetzidis A, Valsami G, Macheras P. Identification of biowaivers among class II drugs: theoretical justification and practical examples. Pharm Res 2004 21 : 1567 1572.
13. Rinaki E, Valsami G, Macheras P. Quantitative biopharmaceutics classification system: the central role of dose/solubility ratio. Pharm Res 2003 20 : 1917 1925.
14. Fagerholm U. Evaluation and suggested improvements of the biopharmaceutics classification system (BCS). J Pharm Pharmacol 2007 59 : 751 757.
15. Papadopoulou V, Valsami G, Dokoumetzidis A, Macheras P. Biopharmaceutics classification systems for new molecular entities (BCS-NMEs) and marketed drugs (BCS-MD): theoretical basis and practical examples. Int J Pharm 2008 361 : 70 7.
16. Zakeri-Milani P, Barzegar-Jalali M, Azimi M, Valizadeh H. Biopharmaceutical classification of drugs using intrinsic dissolution rate (IDR) and rat intestinal permeability. Eur J Pharm Biopharm 2009 73 : 102 106.
17. Dokoumetzidis A, Macheras P. A century of dissolution research: from Noyes and Whitney to the Biopharmaceutics Classification System. Int J Pharm 2006 321 : 1 11.
18. Noyes AA, Whitney WR. The rate of solution of solid substances in their own solutions. J Am Chem Soc 1897 19 : 930 934.
19. Nernst W. Theorie der reaktionsgeschwindigkeit in heterogenen systemen. Z Phys Chem 1904 47 : 52 5.
20. Brünner E. Reaktionsgeschwindigkeit in heterogenen systemen. Z Phys Chem 1904 47 : 56 102.
21. Sugano K. Theoretical comparison of hydrodynamic diffusion layer models used for dissolution simulation in drug discovery and development. Int J Pharm 2008 363 : 73 7.
22. Dokoumetzidis A, Papadopoulou V, Valsami G, Macheras P. Development of a reaction-limited model of dissolution: application to official dissolution tests experiments. Int J Pharm 2008 355 : 114 125.
23. Levich V. Physicochemical Hydrodynamics. Prentice Hall, Englewood Cliffs, NJ, 1962.
24. Wood JH, Syarto JE, Letterman H. Improved holder for disk intrinsic dissolution rate studies. J Pharm Sci 1965 54 : 1068.
25. D'Arcy DM, Corrigan OI, Healy AM. Evaluation of hydrodynamics in the basket dissolution apparatus using computational fluid dynamics - dissolution rate implications. Eur J Pharm Sci 2006 27 : 259 267.
26. D'Arcy DM, Healy AM, Corrigan OI. Towards determining appropriate hydrodynamic conditions for in vitro in vivo correlations using computational fluid dynamics. Eur J Pharm Sci 2009 37 : 291 299.
27. Kakhi M. Mathematical modeling of the fluid dynamics in the flow-through cell. Int J Pharm 2009 376 : 22 40.
28. Macheras P, Argyrakis P. Gastrointestinal drug absorption: is it time to consider heterogeneity as well as homogeneity? Pharm Res 1997 14 : 842 847.
29. Weitschies W, Wedemeyer RS, Kosch O, Fach K, Nagel S, Söderlind E et al. Impact of the intragastric location of extended release tablets on food interactions. J Control Release 2005 108 : 375 385.
30. Macheras PE, Koupparis MA, Antimisiaris SG. Drug binding and solubility in milk. Pharm Res 1990 7 : 537 541.
31. Galia E, Nicolaides E, Hörter D, Löbenberg R, Reppas C, Dressman JB. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm Res 1998 15 : 698 705.
32. Kostewicz ES, Brauns U, Becker R, Dressman JB. Forecasting the oral absorption behavior of poorly soluble weak bases using solubility and dissolution studies in biorelevant media. Pharm Res 2002 19 : 345 349.
33. Ghazal HS, Dyas AM, Ford JL, Hutcheon GA. In vitro evaluation of the dissolution behaviour of itraconazole in bio-relevant media. Int J Pharm 2009 366 : 117 123.
34. Vertzoni M, Pastelli E, Psachoulias D, Kalantzi L, Reppas C. Estimation of intragastric solubility of drugs: in what medium? Pharm Res 2007 24 : 909 917.
35. Pedersen BL, Müllertz A, Brøndsted H, Kristensen HG. A comparison of the solubility of danazol in human and simulated gastrointestinal fluids. Pharm Res 2000 17 : 891 894.
36. Dressman JB, Vertzoni M, Goumas K, Reppas C. Estimating drug solubility in the gastrointestinal tract. Adv Drug Deliv Rev 2007 59 : 591 602.
37. Clarysse S, Psachoulias D, Brouwers J, Tack J, Annaert P, Duchateau G et al. Postprandial changes in solubilizing capacity of human intestinal fluids for BCS class II drugs. Pharm Res 2009 26 : 1456 1466.
38. Dokoumetzidis A, Macheras P. IVIVC of controlled release formulations: physiological-dynamical reasons for their failure. J Control Release 2008 129 : 76 8.
39. Bani-Jaber A, Hamdan I, Al-Khalidi B. Sodium mefenamate as a solution for the formulation and dissolution problems of mefenamic acid. Chem Pharm Bull 2007 55 : 1136 1140.
40. Matteucci ME, Paguio JC, Miller MA, Williams 3rd. RO, Johnston KP. Highly supersaturated solutions from dissolution of amorphous itraconazole microparticles at pH 6.8. Mol Pharm 2009 6 : 375 385.
41. Florence AJ. The solid state. In: Florence TA, Siepman J (eds). Modern Pharmaceutics, Vol. 1. Basic Principles and Systems. Informa Healthcare, New York, 2009 253 310.
42. Matteucci ME, Paguio JC, Miller MA, Williams Iii RO, Johnston KP. Flocculated amorphous nanoparticles for highly supersaturated solutions. Pharm Res 2008 25 : 2477 2487.
43. Schmidt J, Vogelsberger W. Dissolution kinetics of titanium dioxide nanoparticles: the observation of an unusual kinetic size effect. J Phys Chem B 2006 110 : 3955 3963.
44. Box KJ, Völgyi G, Baka E, Stuart M, Takács-Novák K et al. Equilibrium versus kinetic measurements of aqueous solubility, and the ability of compounds to supersaturate in solution - A validation study. J Pharm Sci 2006 95 : 1298 1306.
45. Box KJ, Comer JE. Using measured pKa, logP and solubility to investigate supersaturation and predict BCS class. Curr Drug Metab 2008 9 : 869 878.
46. Kostewicz ES, Wunderlich M, Brauns U, Becker R, Bock T, Dressman JB. Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine. J Pharm Pharmacol 2004 56 : 43 51.
47. Sugano K. A simulation of oral absorption using classical nucleation theory. Int J Pharm 2009 378 : 142 145.
48. Miyamoto S. A theory of the rate of solution of solid into liquid. Trans Faraday Soc 1933 29 : 789 794.
49. Dokoumetzidis A, Macheras P. A population growth model of dissolution. Pharm Res 1997 14 : 1122 1126.
50. Lánský P, Weiss M. Does the dose-solubility ratio affect the mean dissolution time of drugs? Pharm Res 1999 16 : 1470 1476.